Rapid scaling-up of antiretroviral therapy in 10 000 adults in Côte d'Ivoire: 2-year outcomes and determinants
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE: To assess the rates and determinants of mortality, loss to follow-up and immunological failure in a nongovernmental organization-implemented program of access to antiretroviral treatment in Côte d'Ivoire. METHODS: In each new treatment center, professionals were trained in HIV care, and a computerized data system was implemented. Individual patient and program level determinants of survival, loss to follow-up and immunological failure were assessed by multivariate analysis. RESULTS: Between May 2004 and February 2007, 10,211 patients started antiretroviral treatment in 19 clinics (median preantiretroviral treatment CD4 cell count, 123 cells/microl; initial regimen zidovudine-lamivudine-efavirenz, 20%; stavudine-lamivudine-efavirenz, 22%; stavudine-lamivudine-nevirapine, 52%). At 18 months on antiretroviral treatment, the median gain in CD4 cell count was +202 cells/microl, the probability of death was 0.15 and the probability of being loss to follow-up was 0.21. In addition to the commonly reported determinants of impaired outcomes (low CD4 cell count, low BMI, low hemoglobin, advanced clinical stage, old age and poor adherence), two factors were also shown to independently jeopardize prognosis: male sex (men vs. women: hazard ratio = 1.52 for death, 1.27 for loss to follow-up, 1.31 for immunological failure); and attending a recently opened clinic (inexperienced vs. experienced centers: hazard ratio = 1.40 for death, 1.58 for loss to follow-up). None of the three outcomes was associated with the drug regimen. DISCUSSION: In this rapidly scaling-up program, survival and immune reconstitution were good; women and patients followed up in centers with longer experience had better outcomes; outcomes were similar in zidovudine/stavudine-based regimens and in efavirenz/nevirapine-based regimens. Decreasing the rate of loss to follow-up should now be the top priority in antiretroviral treatment rollout.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa
Lawn, S. D., Harries, A. D., Anglaret, X., Myer, L., & Wood, R. (2008) · AIDS · doi:10.1097/qad.0b013e32830007cd · Cited by 639
Self-citationFox, M. P., & Rosen, S. (2010) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2010.02508.x · Cited by 559
Fox, M. P., & Rosen, S. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000553 · Cited by 306
Scaling up in international health: what are the key issues?
Mangham, L. J., & Hanson, K. (2010) · Health Policy and Planning · doi:10.1093/heapol/czp066 · Cited by 303
Gupta, A., Nadkarni, G., Yang, W.-T., Chandrasekhar, A., Gupte, N., Bisson, G. P., Hosseinipour, M., & Gummadi, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028691 · Cited by 254
May, M., Boulle, A., Phiri, S., Messou, E., Myer, L., Wood, R., Keiser, O., Sterne, J. A., Dabis, F., & Egger, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60666-6 · Cited by 250
Self-citationKigozi, I. M., Dobkin, L. M., Martin, J. N., Geng, E. H., Muyindike, W., Emenyonu, N. I., Bangsberg, D. R., & Hahn, J. A. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181ab6eab · Cited by 163
Frijters, E. M., Hermans, L. E., Wensing, A. M. J., Devillé, W. L. J. M., Tempelman, H. A., & De Wit, J. B. F. (2020) · AIDS · doi:10.1097/qad.0000000000002523 · Cited by 75
“As a result of inconsistent categorization between studies for haemoglobin level [28,30,39,41,43, 68,84,89,102,108], alcohol use [21,36,40,52,77] and clinic size [20,27,29,39,45,64,91,102] no meta-analysis could be performed.”
BackgroundNsanzimana, S., Ruton, H., Lowrance, D. W., Cishahayo, S., Nyemazi, J. P., Muhayimpundu, R., Karema, C., Raghunathan, P. L., Binagwaho, A., & Riedel, D. J. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31823e2278 · Cited by 48
“For example, in 2005, 65% of patients in Rwanda were WHO stage 3 or 4 at ART initiation; this percentage was similar in 2004 to that in Malawi (82%),(2) Zambia (73%),(3) and Ivory Coast (81%).(6) Because earlier treatment usually yields improved FIGURE 3.”
ResultJaquet, A., Wandeler, G., Nouaman, M., Ekouevi, D. K., Tine, J., Patassi, A., Coffie, P. A., Tanon, A., Seydi, M., Attia, A., et al. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21424 · Cited by 38
Self-citation
Metadata
- Authors
- Toure, S., Kouadio, B., Seyler, C., Traore, M., Dakoury-Dogbo, N., Duvignac, J., Diakite, N., Karcher, S., Grundmann, C., Marlink, R., Dabis, F., & Anglaret, X.
- Venue
- AIDS
- Published
- 2008-04-23
- Volume
- 22
- Issue
- 7
- Pages
- 873-882
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2064871165
- Cited by
- 185
- References
- 0
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.